Findings from a phase 2 clinical study indicated that neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab, and pertuzumab demonstrated promising efficacy and safety in the treatment of HER2-positive breast cancer.
Treatment with a neoadjuvant combination of pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab (Herceptin), pertuzumab (Perjeta), and a taxane could be a safe and effective treatment option for patients with HER2-positive breast cancer, according to preliminary results from a single-arm phase 2 study that were presented at the 2022 European Society for Medical Oncology (ESMO) Congress.
Data Show Barriers to Immunotherapy Access in Clear Cell RCC Population
December 1st 2023Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Trastuzumab Deruxtecan Showcases Clinical Efficacy in HER2+ Gynecological Cancers
November 20th 2023Data from the phase 2 DESTINY-PanTumor02 trial support trastuzumab deruxtecan as a potential treatment for patients with gynecologic HER2-expressing tumors that have progressed on prior therapy.